<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00069940</url>
  </required_header>
  <id_info>
    <org_study_id>03-365</org_study_id>
    <secondary_id>P30CA006516</secondary_id>
    <nct_id>NCT00069940</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy and Sargramostim in Treating Patients With Sarcoma or Brain Tumor</brief_title>
  <official_title>A Phase I Study Of Vaccination With Telomerase Peptide Plus GM-CSF</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.
      Colony-stimulating factors such as sargramostim increase the number of immune cells found in
      bone marrow or peripheral blood. Combining vaccine therapy with sargramostim may cause a
      stronger immune response and kill more tumor cells.

      PURPOSE: This phase I trial is studying the side effects of vaccine therapy when given
      together with sargramostim in treating patients with advanced sarcoma or brain tumor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility of treatment with telomerase: 540-548 peptide vaccine and
           sargramostim (GM-CSF) in patients with sarcoma or brain tumor.

        -  Determine the safety and tolerability of this regimen in these patients.

        -  Determine the frequency of T-cell specific vaccine antigens during and after
           administration of this regimen in these patients.

        -  Determine, preliminarily, the clinical response, if any, of patients treated with this
           regimen.

      OUTLINE: Patients receive telomerase: 540-548 peptide vaccine subcutaneously (SC) on day 3
      and sargramostim (GM-CSF) SC on days 1-4 of weeks 1, 3, 5, 7, 9, 11, 15, 19, and 23.

      PROJECTED ACCRUAL: A total of 35 patients (20 adult and 15 pediatric) will be accrued for
      this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2000</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <condition>Sarcoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>telomerase: 540-548 peptide vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed diagnosis of 1 of the following
             malignancies:

               -  Stage III or IV sarcoma, including:

                    -  Leiomyosarcoma

                    -  Synovial cell sarcoma

                    -  Liposarcoma

                    -  Gastrointestinal stromal tumor

               -  Brain tumor, including:

                    -  Diffuse pontine glioma*

                    -  Glioblastoma multiforme

                    -  Glialsarcoma NOTE: *For patients with diffuse pontine glioma, the
                       requirement for histologic verification may be waived

          -  No known curative therapy

          -  HLA A*0201 positive by genotyping

        PATIENT CHARACTERISTICS:

        Age

          -  Over 2

        Performance status

          -  Karnofsky 60-100% (patients over age 16)

          -  Lansky 60-100% (patients under age 16)

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC greater than 3,000/mm^3

          -  Absolute neutrophil count greater than 1,500/mm^3

          -  Platelet count greater than 100,000/mm^3

        Hepatic

          -  AST and ALT less than 2.5 times upper limit of normal (ULN)

          -  Bilirubin less than 1.5 times ULN

        Renal

          -  Creatinine less than 1.5 times ULN

        Cardiovascular

          -  No clinically significant cardiovascular disease

        Pulmonary

          -  No clinically significant pulmonary disease

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  No prior hematopoietic stem cell transplantation

          -  No other concurrent vaccine therapy

          -  No other concurrent immunotherapy

        Chemotherapy

          -  No prior chemotherapy

          -  No concurrent chemotherapy

        Endocrine therapy

          -  Concurrent dexamethasone allowed provided patient has been on a decreasing dose for
             the past 2 weeks and the current dose is the lowest clinically acceptable dose
             (ideally, less than 9-12 mg/day)

        Radiotherapy

          -  No prior extensive-field radiotherapy that would compromise bone marrow function

          -  At least 2 weeks since prior local radiotherapy

        Surgery

          -  At least 2 weeks since prior surgery

        Other

          -  At least 2 weeks since prior imatinib mesylate

          -  No concurrent local anesthetic to administration site of vaccine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. Nicholas Haining, BM, BCh</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>December 26, 2010</last_update_submitted>
  <last_update_submitted_qc>December 26, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>William Haining, MD</name_title>
    <organization>Dana-Farber Cancer Institute</organization>
  </responsible_party>
  <keyword>adult glioblastoma</keyword>
  <keyword>stage III adult soft tissue sarcoma</keyword>
  <keyword>stage IV adult soft tissue sarcoma</keyword>
  <keyword>adult synovial sarcoma</keyword>
  <keyword>childhood synovial sarcoma</keyword>
  <keyword>childhood leiomyosarcoma</keyword>
  <keyword>adult leiomyosarcoma</keyword>
  <keyword>adult liposarcoma</keyword>
  <keyword>childhood liposarcoma</keyword>
  <keyword>gastrointestinal stromal tumor</keyword>
  <keyword>recurrent childhood brain tumor</keyword>
  <keyword>recurrent adult brain tumor</keyword>
  <keyword>metastatic childhood soft tissue sarcoma</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>recurrent adult soft tissue sarcoma</keyword>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <keyword>adult anaplastic astrocytoma</keyword>
  <keyword>adult oligodendroglioma</keyword>
  <keyword>adult anaplastic oligodendroglioma</keyword>
  <keyword>adult diffuse astrocytoma</keyword>
  <keyword>adult mixed glioma</keyword>
  <keyword>adult myxopapillary ependymoma</keyword>
  <keyword>adult anaplastic ependymoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

